Oligonucleotide Therapeutics
•7 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (7)
%
| Company | Market Cap | Price |
|---|---|---|
|
Avidity's platform delivers oligonucleotide therapeutics using antibody targeting (AOC), directly making oligonucleotide therapeutics.
|
$5.18B |
$42.95
+3.74%
|
|
Elsunersen and related assets are antisense oligonucleotides, fitting the oligonucleotide therapeutics category.
|
$859.98M |
$47.67
-1.37%
|
|
Imetelstat is an oligonucleotide-based telomerase inhibitor used to treat hematologic malignancies (lower-risk MDS) and is Geron's lead therapeutic.
|
$808.89M |
$1.27
+0.39%
|
|
Oligonucleotide Therapeutics: Korro Bio uses an oligonucleotide-based approach (OPERA) for RNA editing to therapeutically modify RNA.
|
$403.51M |
$42.97
-8.18%
|
|
PepGen's business revolves around oligonucleotide therapeutics, a major, investable category with many public peers.
|
$154.28M |
$4.71
-3.78%
|
|
The siRNA asset falls under oligonucleotide therapeutics, a distinct therapeutic modality leveraged by BFRG.
|
$13.56M |
$1.44
-4.64%
|
|
Ampligen is a dsRNA oligonucleotide therapeutic, placing AIM in the oligonucleotide therapeutics space.
|
$1.93M |
$2.52
-3.45%
|
Loading industry metrics...
Loading comparison data...
